256.56

12.26% -35.86

Bio Rad Laboratories Inc (BIO)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$292.42

Aprire:

$251

Volume 24 ore:

1.06M

Relative Volume:

5.09

Capitalizzazione di mercato:

$6.92B

Reddito:

$2.58B

Utile/perdita netta:

$-778.69M

Rapporto P/E:

-9.3875

EPS:

-27.33

Flusso di cassa netto:

$223.75M

1 W Prestazione:

-14.91%

1M Prestazione:

-20.37%

6M Prestazione:

-10.66%

1 anno Prestazione:

-16.26%

Intervallo 1D:

$251.00

$272.79

Intervallo di 1 settimana:

$251.00

$301.47

Portata 52W:

$211.43

$343.12

Bio Rad Laboratories Inc Stock (BIO) Company Profile

Nome

Bio Rad Laboratories Inc

Settore

Healthcare (1111)

Industria

Medical Devices (139)

Telefono

(510) 724-7000

Indirizzo

1000 ALFRED NOBEL DRIVE, HERCULES

Dipendente

7,700

Cinguettio

@BioRadLifeSci

Prossima data di guadagno

2024-10-30

Ultimi documenti SEC

BIO's Discussions on Twitter

Compare BIO vs ABT, SYK, MDT, BSX, EW

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BIO Bio Rad Laboratories Inc	256.56	7.89B	2.58B	-778.69M	223.75M	-27.33
ABT Abbott Laboratories	112.68	193.83B	44.33B	6.48B	6.92B	3.7033
SYK Stryker Corp	366.05	140.01B	25.12B	3.25B	4.28B	8.3984
MDT Medtronic Plc	99.49	129.33B	34.76B	4.79B	5.21B	3.7017
BSX Boston Scientific Corp	74.73	109.92B	20.08B	2.89B	3.82B	1.9391
EW Edwards Lifesciences Corp	75.87	44.36B	6.07B	1.06B	799.60M	1.8527

Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-01	Aggiornamento	Citigroup	Neutral → Buy
2024-08-28	Iniziato	Wells Fargo	Equal Weight
2024-06-03	Ripresa	Jefferies	Hold
2024-04-03	Downgrade	Citigroup	Buy → Neutral
2023-12-07	Iniziato	UBS	Buy
2023-06-16	Iniziato	Wells Fargo	Overweight
2022-12-07	Iniziato	RBC Capital Mkts	Outperform
2022-08-25	Iniziato	Credit Suisse	Outperform
2022-01-28	Reiterato	Citigroup	Buy
2020-01-08	Iniziato	Wells Fargo	Overweight
2020-01-07	Iniziato	Citigroup	Buy
2018-10-17	Iniziato	Goldman	Buy
2018-09-20	Iniziato	Morgan Stanley	Equal-Weight
2018-02-16	Downgrade	CL King	Buy → Neutral
2017-07-13	Iniziato	Wells Fargo	Outperform
2017-06-28	Aggiornamento	Deutsche Bank	Hold → Buy
2017-01-18	Iniziato	Deutsche Bank	Hold
2016-10-13	Iniziato	CL King	Buy
2015-05-06	Reiterato	Jefferies	Buy
2009-12-18	Iniziato	Maxim Group	Buy
2009-11-06	Iniziato	Jefferies & Co	Buy
2009-07-17	Iniziato	Soleil	Buy
2007-09-26	Iniziato	Banc of America Sec	Buy
2007-02-23	Downgrade	Robert W. Baird	Outperform → Neutral

Mostra tutto

Bio Rad Laboratories Inc Borsa (BIO) Ultime notizie

01:45 AM

Bio-Rad Laboratories (NYSE:BIO) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat

01:45 AM

12:53 PM

Beyond the Balance Sheet: What SWOT Reveals About Bio-Rad Labora - GuruFocus

12:53 PM

Feb 13, 2026

Bio-Rad Q4 2025 slides reveal modest growth amid segment divergence and strategic shifts - Investing.com Nigeria

Feb 13, 2026

Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap DownHere's What Happened - MarketBeat

Feb 13, 2026

Bio-Rad Laboratories (NYSE:BIO) Shares Gap Down After Earnings Miss - MarketBeat

Feb 13, 2026

Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga

Feb 13, 2026

S&P 500 Futures Drop in Premarket Trading; Pinterest, Bio-Rad Labs A Lag - Barron's

Feb 13, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Feb 13, 2026

BIO-RAD LABORATORIES, INC. SEC 10-K Report - TradingView

Feb 13, 2026

Bio-Rad (BIO) Reports Q4 Revenue Growth and Strategic Initiatives - GuruFocus

Feb 13, 2026